Clinical Trials and Studies
Some clinical trials have suspended enrollment until further notice due to COVID-19 considerations.
Blood Disorders and Hematologic Cancers
- AB-101 with or without Rituximab for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Acute Myeloid Leukemia: Venetoclax and Azacitidine Study
- Assessing the Anti-Tumor Activity and Safety of REGN1979 in Patients with Relapsed or Refractory Follicular Lymphoma
- Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients (VICD)
- CGT9486 Treatment for Advanced Systemic Mastocytosis
- Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease Treatment Study
- Conditioning Therapy for Patients with MDS/AML Undergoing Hematopoietic Cell Transplantation
- Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria
- Danicopan Plus C5 Inhibitor Therapy in Paroxysmal Nocturnal Hemoglobinuria
- Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype Treatment Study
- Drug Treatment Study for Children with Hemophilia A
- Drug Treatment Study for High Grade B-Cell Lymphomas
- Drug Treatment Study for Patients with Follicular Lymphoma
- Evaluation of Pediatric Palliative Inpatient Process
- FLT3 Mutated Acute Myeloid Leukemia Treatment Study
- Follicular Lymphoma Treatment Study
- Health Literacy and Numeracy in Adolescent Patients with Hemophilia A and B Study
- Hemophilia A or B Treatment Study
- Hemophilia A Treatment Study
- Hodgkin Lymphoma and CD30-Expressing Peripheral T-cell Lymphoma Treatment Study
- Luspatercept Versus Placebo for Treating Subjects with Myelofibrosis on JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
- Luspatercept versus Placebo in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis
- Mantle Cell Lymphoma Treatment Study
- Mapping of CD34+ Cells From Healthy Participants and Patients with Myelofibrosis and Polycythemia Vera
- Molecular and Clinical Biology of von Willebrand Disease Study
- Mosunetuzumab Treatment for DLBCL After First-Line Immunochemotherapy, Alone, or in Combination with Polatuzumab Vedotin for Previously Untreated DLBCL
- Myelofibrosis: Phase 3 Study of Navitoclax Plus Ruxolitinib Versus Ruxolitinib
- National Registry of All Persons with Bleeding and Clotting Disorders
- Newly Diagnosed T-Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma Treatment Study
- Nivolumab and Combination Chemotherapy in Treating Participants with Diffuse Large B-Cell Lymphoma
- Public Health Surveillance for the Prevention of Complications of Bleeding and Clotting Disorders
- Relapsed or Refractory Follicular Lymphoma Treatment Study
- Specimen Collection from ALL or CML Patients for the Xpert BCR-ABL Ultra p190 Test
- Specimen Collection from ALL or CML Patients with a Detectable BCR-ABL p190 Fusion Transcript Level
- Study for Patients with Acute Lymphoblastic Leukemia
- Study for Patients with Acute Myelogenous Leukemia
- Study for Patients with Acute Myeloid Leukemia
- Study for Patients with Non-Advanced Systemic Mastocytosis
- Study for Patients with Primary Immune Thrombocytopenia
- Study for Patients with Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia (AML)
- Study of Biomarkers in Hemophilic Arthropathy
- Study of Hepatitis C Virus Outcomes After Treatment in Patients with Bleeding Disorders
- Study of Uproleselan Administered with Chemotherapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia
- Study Treating Patients With High-Risk Smoldering Myeloma
- Tafasitamab + Lenalidomide + R-CHOP versus R-CHOP to Treat Diffuse Large B-Cell Lymphoma
- Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia
- The National Myelodysplastic Syndromes Study
- Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma Study
- Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma Study
- Treatment Study for Children with Hemophilia B
- Treatment Study for Newly Diagnosed High Risk B-Lymphoblastic Leukemia in Patients with Ph-like TKI Sensitive Mutations
- Treatment Study for Older Patients with Acute Lymphoblastic Leukemia
- Treatment Study for Patients with Diffuse Large B-Cell Lymphoma After aHCT
- Treatment Study for Patients with Localized Central Nervous System Germ Cell Tumors
- Treatment Study for Patients with Marginal Zone Lymphoma
- Treatment Study for Patients with Newly Diagnosed B-Lymphoblastic Leukemia or B-Lineage Lymphoblastic Lymphoma
- Treatment Study for Patients with Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
- Treatment Study for Patients with Rare Tumors
- Treatment Study for Patients with Untreated Mantle Cell Lymphoma
- Treatment Study for Pediatric Patients with Hemophilia A
- Treatment Study for Subjects with Myelofibrosis Who Have Failed a JAK Inhibitor
- Treatment Study for Subjects with Severe Hemophilia A or B
- Treatment Study for Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Venetoclax with Azacitidine for Newly Diagnosed Myelodysplastic Syndrome
- Zandelisib Treatment for Follicular or Marginal Zone Lymphoma After Failure of 2 or More Prior Therapies
Brain Tumors
- A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme
- Genetic Testing in Guiding Treatment for Patients with Brain Metastases
- Meningioma Drug Treatment Study
- Observation or Radiation Therapy in Treating Patients with Newly Diagnosed Grade II Meningioma that has been Completely Removed by Surgery
- Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM (EF-32)
- Radiation Therapy Study for Patients with IDH Mutant Grade II or III Glioma
- Single Fraction Stereotactic Radiosurgery Compared With Fractionated Stereotactic Radiosurgery in Treating Patients With Resected Metastatic Brain Disease
- Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability
- The MATCH Screening Trial
Breast Cancer
- A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer (EMBER-3)
- Breast Cancer Collaborative Registry
- CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-Surgery Chemo and Targeted Therapy
- Estrogen Receptor Status Study
- Radiation Therapy Treatment Study for Patients with Early-Stage Breast Cancer
- Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer
- Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
- Study Assessing the Accuracy of Tumor Biopsies After Chemotherapy
- Study of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer (TAILOR RT)
- The CompassHER2 RD Trial for High Risk HER2-Positive Breast Cancer
- The MATCH Screening Trial
- The ZEST Study for Patients with HER2 Negative or Triple Negative Breast Cancer
- Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer
- Treating Patients With Triple-Negative Breast Cancer
Gastrointestinal Cancers
- Adenoma and Second Primary Prevention Trial
- Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas Treatment Study
- Advanced/Metastatic Colorectal Cancer with HER-2 Amplification Treatment Study
- BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer
- Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery
- Colonoscopy Research Study
- Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study
- Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer
- EA2176: Phase 3 Clinical Trial of Carboplatin and Pacliitaxel +/- Nivolumab in Metastatic Anal Cancer Patients
- Growth of Colon Tissue to Evaluate GI
- High Risk Anal Cancer Treatment Study
- Initial Feasibility Study to Treat Pancreatic Cancer With a Planar LDR Source
- Oral Health Study
- PANOVA-3 Study for Patients with Locally-Advanced Pancreatic Adenocarcinoma
- Polyp Removal Research Study
- Refractory Small Bowel Adenocarcinoma Treatment Study
- Retrospective Chart Review of Patients with Fibrolamellar Carcinoma
- Study for Patients Who are Eligible for Colorectal Cancer Screening Screening
- Study for Patients with Colorectal Cancer or Colorectal Lesion
- Study for Patients with Hepatocellular Carcinoma (HCC)
- Study for Patients with Hepatocellular Carcinoma (HCC)
- Study of Eating Patterns and Alcohol Consumption in Patients with Advanced Tubular Adenoma
- Testing Diet Intervention Versus Non-Diet Intervention for Management of Bowel Symptoms in Rectal Cancer Survivors
- The BP-012 Study for Patients with GI & GU Cancers
- The COMMIT Study: Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer
- The DECREASE Study: Treatment of Early-Stage Anal Cancer
- The MATCH Screening Trial
- Treatment Study for Patients With Stage III Colon Cancer
- Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer
Genitourinary Cancers
- BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Treatment Study
- Chemoradiotherapy Study for Patients with Localized Muscle Invasive Bladder Cancer
- Drug Treatment Study with Radiation in Advanced Tumors
- Endometrial Cancer Medication Treatment Study
- Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study
- Novel Treatment Combination Study for Metastatic Prostate Cancer Patients
- Phase 1 Study for Urothelial Cancer
- Prostate Cancer Study
- Study of Combination Therapy for High Risk Prostate Cancer
- Study of Standard Systemic Therapy in Treating Prostate Cancer
- Study of the NanoKnife System for the Ablation of Prostate Tissue
- Study to Test Radium-223 with Docetaxel in Patients with Prostate Cancer
- Systematic Light Exposure to Prevent Fatigue in Prostate Cancer Patients
- The BP-012 Study for Patients with GI & GU Cancers
- The CASPAR Trial for Men with Metastatic Prostate Cancer that has become Resistant to Testosterone-Deprivation Therapy
- The ICONIC Trial for Rare Genitourinary Cancers
- The PREDICT-RT Trial for Patients with High Risk Prostate Cancer
- The PROBE Trial: Treatment Study for Metastatic Kidney Cancer
- The RadiCaL Study: Testing the Addition of a New Anti-Cancer Drug to the Usual Treatment for Advanced Renal Cell Cancer that has Spread to the Bone
- Treating Participants With Metastatic Prostate Cancer
- Treating Patients With High Risk Prostate Cancer
- Treating Patients With Metastatic, Castration-Resistant Prostate Cancer
- Treatment Study for Node-Positive Prostate Cancer After Radical Prostatectomy
- Treatment Study for Patients With Localized Muscle Invasive Bladder Cancer
- Treatment Study for Patients With Locally Advanced Bladder Cancer
- Treatment Study for Patients With Muscle-Invasive Bladder Cancer
- Treatment Study for Patients with Prostate Cancer
- Treatment Study for Patients with Prostate Cancer with DNA Repair Defects
- Treatment Study for Rare Genitourinary Cancers
- Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy
Gynecologic Cancers
- Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
- Study to Compare Two Surgical Procedures in Women With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- Treatment Study for Advanced-Stage Cervical and Vaginal Cancers
- Treatment Study for Patients with Stage I-IIA Cervical Cancer
- Treatment with Pembrolizumab/Placebo with Carboplatin and Paclitaxel for Advanced Stage or Recurrent Endometrial Cancer
Head and Neck Cancer
- Advanced Pneumatic Compression Device
- Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
- HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer Treatment Study
- Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
- Lenvatinib in Combination with Pembrolizumab vs. Standard Chemotherapy in Head and Neck Cancer
- Locoregionally Advanced Head and Neck Cancer Treatment Study
- Nasal and Paranasal Sinus Cancer Treatment Study
- Nasal and Paranasal Sinus Squamous Cell Carcinoma Treatment Study
- Oropharyngeal Cancer Treatment Study
- Photoimmunotherapy Study in Recurrent Head and Neck Cancer
- Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
- Testing Immunotherapy Versus Observation in Patients with HPV Throat Cancer
- The ASPEN-03 Study for Patients with Head and Neck Cancer
- The ASPEN-04 Study for Patients with Head and Neck Cancer
- Treatment Study for Squamous Cell Carcinoma of the Head and Neck
Lung and Chest Tumors
- A Lung-MAP Non-Match Treatment Trial: Treating Patients with Stage IV or Recurrent Non-Small Cell Lung Cancer
- A LUNG-MAP Treatment Trial: Combination Treatment for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation
- A LUNG-MAP Treatment Trial: Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer
- A Lung-MAP Treatment Trial: Treating Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer
- A Study of SEA-CD40 Given With Other Drugs in Cancers
- ALCHEMIST Chemo-IO Study: Treatment for Treatment for Non-Small Cell Lung Cancer
- An ALCHEMIST Treatment Trial: Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer
- Chemoradiation With or Without Atezolizumab in Treating Patients with Limited Stage Small Cell Lung Cancer
- Drug Treatment Study for Small Cell Lung Cancer
- Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
- Maintenance Chemotherapy Study in Treating Patients With Stage IV Non-small Cell Lung Cancer
- Management of Tobacco Treatment Intervention in Reducing Surgical Complications in Patients With Newly Diagnosed Lung Cancer
- Pulmonary and Critical Care Repository
- Study of Advanced Non-Small Cell Lung Cancer that has Progressed on First-Line Osimertinib Therapy
- Study of First Line Treatment and Maintenance in Non-Small Cell Lung Cancer
- Study of Immunotherapy Alone or with Chemotherapy as Treatment in Non-Small Cell Lung Cancer
- Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
- Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability
- Testing the Addition of an Antibody to Standard Chemoradiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
- The (TKI)-naïve Study for Patients with NSCLC
- The ALCHEMIST Screening Trial: Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer
- The MAVERICK Trial for Small-Cell Lung Cancer
- Treatment Study for Patients with Newly Diagnosed Stage III Non-Small Cell Lung Cancer
- Treatment Study of Pill Chemotherapy Compared to Standard Chemotherapy for Non-Small Cell Lung Cancer
Melanoma and Soft Tissue
- A Prospective Disease Registry of Patients with Mantle Cell Lymphoma Treated with Novel Agents
- A Study of SEA-CD40 Given With Other Drugs in Cancers
- BNT-111 for Treatment of Advanced Melanoma
- Drug Treatment Study with Radiation in Advanced Tumors
- Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C Melanoma Patients (Neo-DREAM)
- ITIL-168 in Advanced Melanoma (DELTA-1)
- STAMP Study: Treating Patients With Completely Resected Stage I-III Merkel Cell Cancer
- Treating Patients With Advanced Skin Squamous Cell Cancer
- Treatment Study for Patients With Desmoplastic Melanoma
- Treatment Study for Patients with Unresectable Stage III or Stage IV Melanoma
- UV1-202 Vaccine Study in Combination with Nivolumab and Ipilimumab for Melanoma